| 37.03 1.26 (3.52%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.71  |
1-year : | 55.72 |
| Resists | First : | 40.84 |
Second : | 47.71 |
| Pivot price | 34.89 |
|||
| Supports | First : | 35.29 |
Second : | 31.86 |
| MAs | MA(5) : | 35.9 |
MA(20) : | 34.51 |
| MA(100) : | 34.85  |
MA(250) : | 36.1 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 83.1 |
D(3) : | 79.2 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 45.97 | Low : | 28.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VCEL ] has closed Bollinger Bands are 15.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.75 - 37.9 | 37.9 - 38.03 |
| Low: | 36.02 - 36.2 | 36.2 - 36.36 |
| Close: | 36.71 - 37.01 | 37.01 - 37.27 |
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Tue, 09 Jun 2026
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026 - Yahoo Finance
Sun, 07 Jun 2026
Price-Driven Insight from (VCEL) for Rule-Based Strategy - Stock Traders Daily
Thu, 04 Jun 2026
Vericel (VCEL) CMO sells 4,375 shares after option exercise - Stock Titan
Thu, 04 Jun 2026
Vericel (NASDAQ:VCEL) Balances High Growth and Reasonable Valuation in Affordable Growth Screen - ChartMill
Tue, 02 Jun 2026
Proposed sale of 4,375 VCEL shares (NASDAQ: VCEL) - Stock Titan
Mon, 18 May 2026
Vericel (VCEL) amends bylaws to reflect new Burlington, MA global headquarters - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 111.2 (%) |
| Shares Short | 5,340 (K) |
| Shares Short P.Month | 5,080 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.98 |
| Profit Margin | 7.3 % |
| Operating Margin | -11.8 % |
| Return on Assets (ttm) | 2.1 % |
| Return on Equity (ttm) | 6.5 % |
| Qtrly Rev. Growth | 30.1 % |
| Gross Profit (p.s.) | 4.28 |
| Sales Per Share | 5.71 |
| EBITDA (p.s.) | 0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 42 (M) |
| PE Ratio | 86.11 |
| PEG Ratio | 0 |
| Price to Book value | 5.3 |
| Price to Sales | 6.47 |
| Price to Cash Flow | 30.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|